Blood Res.  2015 Dec;50(4):189-191. 10.5045/br.2015.50.4.189.

A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies

• Kim HS

• KMID: 2133751
• DOI: http://doi.org/10.5045/br.2015.50.4.189

Abstract

No abstract available.

MeSH Terms

Hematologic Neoplasms*
Killer Cells, Natural*

Figure

• 

  Fig. 1 Strategies aiming at enhancing natural killer (NK) cell reactivity against cancer. Several strategies have been developed to restore or enhance tumor eradication by NK cells: blockade of inhibition, enhancement of activation, or augmentation of tumor susceptibility. These strategies may be combined in a cooperative way to optimize NK cell-based cancer immunotherapy depending on the context.

Reference

1. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013; 31:227–258. PMID: 23516982.

2. Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. 2015; 6:578. PMID: 26635792.

3. Chouaib S, Pittari G, Nanbakhsh A, et al. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol. 2014; 5:95. PMID: 24672522.

4. Watzl C. How to trigger a killer: modulation of natural killer cell reactivity on many levels. Adv Immunol. 2014; 124:137–170. PMID: 25175775.

5. Cerboni C, Fionda C, Soriani A, et al. The DNA damage response: A common pathway in the regulation of nkg2d and dnam-1 ligand expression in normal, infected, and cancer cells. Front Immunol. 2014; 4:508. PMID: 24432022.

6. Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S. Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Front Immunol. 2015; 6:230. PMID: 26029215.

7. Chretien AS, Le Roy A, Vey N, et al. Cancer-induced alterations of NK-mediated target recognition: Current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol. 2014; 5:122. PMID: 24715892.

8. Kwon HJ, Kwon SJ, Lee H, et al. NK cell function triggered by multiple activating receptors is negatively regulated by glycogen synthase kinase-3β. Cell Signal. 2015; 27:1731–1741. PMID: 26022178.

9. Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol. 2013; 4:481. PMID: 24391651.

10. Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program. 2013; 2013:234–246. PMID: 24319186.